# Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

> **NCT04191616** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 54 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT04191616
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-06
- **Primary completion:** 2022-11-30
- **Final completion:** 2024-10-01
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191616, "Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT04191616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*